I appreciate your research. In particular I like a lot your logic, "...So this means FDA actually take in consideration of clinical data from China too right? If that is the case...."
If USA FDA validated Prizma based on data provided from Chinese University, what would the chance be for CHINA CFDA to do the same based on data originated from its own country?
Ann: Annual Report to Shareholders, page-57
-
- There are more pages in this discussion • 125 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)